Navigation Links
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Date:11/10/2008

umor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms -- aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database there were nearly 400,000 people in the U.S. with NHL in 2004. The American Cancer Society estimates that in the United States 66,120 people are expected to be diagnosed with NHL in 2008. Additionally, approximately 19,160 are expected to die from this disease in 2008.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

This press re
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
2. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
5. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
6. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
7. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
11. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Weiss LLP is reporting that on July 13, 2015, the ... Bard, the manufacturer of Inferior vena cava (IVC) filters ... agency found at two of Bard,s facilities. Bard was previously ... during Inspectional Observations that occurred on November 18, 2014, through ... , location and on October 6, 2014, through November 25, ...
(Date:7/31/2015)... July 31, 2015 The Physician-Patient Alliance ... on July 28, 2015, "Surviving Your Hospital Stay: ... for Patient Safety." A sentence was ... read: "PPAHS is a member of ... Opioids. For more information on the National Coalition to ...
(Date:7/31/2015)... , July 31, 2015 ... decades of experience, the domestic pharmaceutical industry is strong, ... manufacture products to high international standards. One ... known is in sub-Saharan Africa: Morocco has quietly become ... South Africa . Indeed, Moroccan pharma ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3
... WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., May ... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... evaluating Nexavar® (sorafenib) tablets in patients with locally ... a bevacizumab-containing regimen, which showed that Nexavar was ...
... WASHINGTON, May 18, 2011 Ten percent of cancer patients failed ... a new study published jointly today in the Journal of ... Managed Care ( AJMC ). The study was based on ... over a two-year period from 2007 to 2009. This study has ...
Cached Medicine Technology:Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 2Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 3Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 4Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 5Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 6Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 7Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 8New Study Finds That 10% of Cancer Patients Abandoned Oral Anti-Cancer Drugs 2New Study Finds That 10% of Cancer Patients Abandoned Oral Anti-Cancer Drugs 3New Study Finds That 10% of Cancer Patients Abandoned Oral Anti-Cancer Drugs 4
(Date:8/1/2015)... ... ... reTXT ” was featured on NewsWatch as part of its monthly AppWatch, which takes ... and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the app ... including ones already sent. , While text messaging has more features than it did ...
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... its new store run by GoodThreads. The store can be accessed by visiting ... designs, many of which are customizable. The best part: whenever a product is ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... communicate. Rally Insurance Group, Inc. has re-branded their social media profiles to better ... personal way for consumers to communicate, find information, share insights and opinions. The ...
(Date:7/31/2015)... ... 2015 , ... According to an article published July 2 on ... reach a consensus on the steps that need to be taken to successfully complete ... percent consensus on a series of steps that each surgeon must complete for each ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... announced today that 10 current and prospective Capella University students ... the field of mental health services. Half are pursuing online ... specializations in psychology and counseling. , ... ...
... way at Rush University Medical Center using a small, soft-patch device ... outerwear to close a common hole found in the heart ... strokes and transient ischemic attacks (TIAs) in adults. , ... involved in the trial and one of only 50 sites in ...
... just for newlyweds anymore. , They are also a way ... according to Kansas State University aging experts. , "By law ... residents some privacy," said Gayle Doll, who directs K-State,s Center ... for nursing home residents who want to engage in sexual ...
... of Americans suffering from the chronic inflammatory bowel condition ... due to innovative new surgeries, according to experts at ... of five Crohn,s patients will require some kind of ... advanced, often minimally invasive techniques are sparing precious bowel ...
... now face greater threat from other disease, study says , , ... about twice the risk of developing a non-AIDS cancer as ... Men with HIV were 2.3 times more likely, while women ... develop these other cancers, according to a meta-analysis expected to ...
... developed by Mitchell Sogin of the Marine Biological Laboratory ... completed the most precise survey to date of how ... treatment. , Sogin, director of the MBL,s Josephine Bay ... with David Relman and Les Dethlefsen of Stanford University, ...
Cached Medicine News:Health News: Capella University Announces $50,000 in Scholarships to Graduate Students in Mental Health Services : Ten students are awarded scholarships at online university 2Health News: Capella University Announces $50,000 in Scholarships to Graduate Students in Mental Health Services : Ten students are awarded scholarships at online university 3Health News: Capella University Announces $50,000 in Scholarships to Graduate Students in Mental Health Services : Ten students are awarded scholarships at online university 4Health News:Study investigates Gore-tex-type device to stop strokes and mini-strokes 2Health News:Study investigates Gore-tex-type device to stop strokes and mini-strokes 3Health News:K-State helps nursing home staff become comfortable with residents' sexual expression 2Health News:Crohn's disease surgeries make steady advances 2Health News:Crohn's disease surgeries make steady advances 3Health News:Non-AIDS Cancer Risk Higher for Those With HIV 2Health News:Antibiotics can cause pervasive, persistant changes to microbiota in human gut 2
... II) is the most potent pressure agent ... active peptide of the renin-angiotensin system (RAS). ... secreted primarily by the juxtaglomerular cells of ... decapeptide angiotensin I (Ang I) which is ...
Troponin I EIA Hypertension/ Cardiac Evaluation 025-BC-1105...
ACTH EIA Hypertension / Cardiac Evaluation, Cardiovascular 021-SDX018...
... Insulin ELISA is a solid phase two-site ... the direct sandwich technique in which two ... determinants on the human insulin molecule. ... with peroxidase-conjugated anti-insulin antibodies and anti-insulin antibodies ...
Medicine Products: